AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7040192
Drug: Progestogen only
RxNorm normalized name: vaginal ring with progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestogen only (Lynestrenol 0.5 mg)
Trial: 7040192
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (ethinyl estradiol 50 micrograms + lynestrenol 2.5 micrograms)
Trial: 31858136
Drug: Shorter treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter treatment duration (5-9 days)
Trial: 31858136
Drug: Longer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer treatment duration (10-15 days)
Trial: 30261877
Drug: Intermittent Screening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Screening and Treatment (ISTp)
Trial: 30261877
Drug: Intermittent Preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Preventive Treatment (IPTp)
Trial: 27381286
Drug: Dose reduction
RxNorm normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose reduction regimen of etanercept (50 mg/week for 4 weeks followed by 25 mg/week for 8 weeks)
Trial: 27381286
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of etanercept (50 mg/week for 12 weeks)
Trial: 23201982
Drug: Pre-treatment stool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment stool samples analysis
Trial: 17577027
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF)
Trial: 15464665
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of reteplase plus abciximab
Trial: 49746
Drug: 95% ethanol
RxNorm normalized name: ALCOHOL 95 mL in 100 mL TOPICAL SOLUTION [95% Ethanol (190 Proof)]
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 95% ethanol solution containing 0‐5% chlorhexidine digluconate applied with a gloved hand for two minutes
Trial: 49746
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution of chlorhexidine applied with a gloved hand
Trial: 49746
Drug: 70% alcoholic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70% alcoholic solution of chlorhexidine applied with a gloved hand
Trial: 28478975
Drug: Adalimumab 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 0.4 mg/kg
Trial: 14672962
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) ingestion (10 ml x kg(‐1) x h(‐1) CHO (6%))
Trial: 9273036
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg lidocaine applied topically to the muscle after opening the conjunctiva
Trial: 29889137
Drug: Mebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebo ointment
Trial: 29889137
Drug: Biafine cream
RxNorm normalized name: BIAFINE CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biafine cream
Trial: 29141665
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) treatment for 6 months
Trial: 26411014
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract 1 (36 mg of PACs)
Trial: 26411014
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract 2 (36 mg of PACs)
Trial: 26411014
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract 3 (36 mg of PACs)
Trial: 12841798
Drug: Emulsion (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion (75 mg/kg)
Trial: 12841798
Drug: Emulsion (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion (150 mg/kg)
Trial: 12841798
Drug: Emulsion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion (300 mg/kg)
Trial: 12841798
Drug: Emulsion (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emulsion (all doses)
Trial: 8850404
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (GM) 2 mg/kg/h in a central venous catheter
Trial: 1626799
Drug: Allergen solution
RxNorm normalized name: catfish allergenic extract
DrugBank: Diphenylpyraline (DB01146)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allergen solution
Trial: 6203289
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg X 3 daily for four weeks
Trial: 31329184
Drug: Comprehensive anti-edematous
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive anti-edematous therapy (CAET)
Trial: 31329184
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy with a conventional lymphovenous tonic and elastic compression (Control)
Trial: 28786423
Drug: Lapatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib treatment
Trial: 28786423
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and taxane combination
Trial: 26763145
Drug: medetomidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medetomidine (10 μg/kg)
Trial: 26763145
Drug: medetomidine with
RxNorm normalized name: medetomidine
DrugBank: Medetomidine (DB11428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medetomidine with MK-467 (250 μg/kg)
Trial: 16269882
Drug: Neostigmine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 1.5 mg and Atropine 0.5 mg
Trial: 12393766
Drug: Ropivacaine 5
RxNorm normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 5 mg ml(-1), 3.5 ml (17.5 mg)
Trial: 12393766
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg ml(-1), 3.5 ml (17.5 mg)
Trial: 9926189
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% 50 mg i.a. (group B)
Trial: 7482412
Drug: 1-desamino-8-D-arginine vasopressin
RxNorm normalized name: 1-desamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-desamino-8-D-arginine vasopressin (DDAVP) infusion
Trial: 528086
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 500 ml dextran 70 during operation and again on the second postoperative day
Trial: 30415629
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (cholecalciferol) at a dose of 2000 IU per day
Trial: 21833551
Drug: L: -carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L: -carnitine supplementation and protein-restricted diet
Trial: 17606725
Drug: Erlotinib (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (single agent)
Trial: 12189358
Drug: Controlled-release flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release flecainide acetate (100 mg/day)
Trial: 12189358
Drug: Controlled-release flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release flecainide acetate (200 mg/day)
Trial: 12189358
Drug: Controlled-release flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release flecainide acetate
Trial: 12189358
Drug: Immediate-release flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release flecainide acetate
Trial: 678389
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg piretanide/day
Trial: 678389
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg frusemide/day
Trial: 678389
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg bumetanide/day
Trial: 678389
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three diuretics
Trial: 24362488
Drug: Ponesimod (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod (10 mg)
Trial: 31266149
Drug: Ponesimod (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod (10 mg) with cenerimod (2 mg once daily) at near half steady-state (Day 18)
Trial: 31266149
Drug: Ponesimod (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponesimod (10 mg) with cenerimod (2 mg once daily) at steady-state (Day 37)
Trial: 31266149
Drug: Cenerimod (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenerimod (2 mg once daily)
Trial: 27728839
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance plus balance training (PRBT) - six months of twice weekly machine-based, moderate to high intensity, supervised training followed by six months of unsupervised follow-up.
Trial: 22580932
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (600,000 IU monthly for 8 weeks)
Trial: 19750476
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.5% bupivacaine with 1:200,000 epinephrine
Trial: 19750476
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of normal saline solution (placebo)
Trial: 15872336
Drug: Peroral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroral estrogen (PE) therapy
Trial: 15872336
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen therapy
Trial: 15872336
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy (combined)
Trial: 10576182
Drug: Topical vaginal
RxNorm normalized name: emollients, topical vaginal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vaginal 5-fluorouracil (5-FU) cream (2 g) for 6 months
Trial: 10576182
Drug: Observation after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation after standard treatment for 6 months
Trial: 1757615
Drug: 0.05% halobetasol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% halobetasol propionate cream
Trial: 2434546
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol 17-propionate cream
Trial: 6925983
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (surgery only)
Trial: 9536449
Drug: Carbamazepine 300
RxNorm normalized name: carbamazepine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine 300 mg/day
Trial: 31017556
Drug: Chicory seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chicory seed supplementation (infused 9 g/d)
Trial: 31017556
Drug: Turmeric supplementation
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric supplementation (3 g/d)
Trial: 31017556
Drug: Turmeric and
RxNorm normalized name: Turmeric
DrugBank: Turmeric (DB14276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric and chicory seed supplementation (3 g/d turmeric + infused 9 g/d chicory seed)
Trial: 26779697
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% 1 mL subcutaneously
Trial: 21946541
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of travoprost eye drops
Trial: 21946541
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of travoprost eye drops
Trial: 21946541
Drug: First month
RxNorm normalized name: Chantix First Month of Therapy Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First month dosing of travoprost eye drops
Trial: 21946541
Drug: Second month
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second month dosing of travoprost eye drops
Trial: 21946541
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing
Trial: 21946541
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing
Trial: 21946541
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing vs Evening dosing
Trial: 19148042
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (3 doses before incision, 8 hours, and 16 hours later)
Trial: 19148042
Drug: Saline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (3 doses before incision, 8 hours, and 16 hours later)
Trial: 14695867
Drug: Glucose Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose Insulin intervention (maintaining euglycaemia)
Trial: 14695867
Drug: Admission plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Admission plasma glucose > or = 6.1 mmol/l and glycosylated haemoglobin > or = 6.2%
Trial: 7809567
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bright light plus goggles
Trial: 29808377
Drug: Fosaprepitant (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosaprepitant (150 mg intravenous single dose)
Trial: 26176994
Drug: Alfentanil 56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 56 μg/kg
Trial: 26176994
Drug: Alfentanil doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil doses (0, 10, 20, 30, 40, 50, 60 μg/kg)
Trial: 26176994
Drug: Thiopental 4
RxNorm normalized name: thiopental 400 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 4 mg/kg and Rocuronium 0.6 mg/kg
Trial: 23357440
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT), 16 sessions of weekly therapy
Trial: 16413556
Drug: Dunaliella capsules
RxNorm normalized name: DUNALIELLA SALINA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dunaliella capsules providing 60 mg beta-carotene/day (first trial)
Trial: 16413556
Drug: Dunaliella capsules
RxNorm normalized name: DUNALIELLA SALINA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dunaliella capsules (second trial)
Trial: 16413556
Drug: Dunaliella capsules
RxNorm normalized name: DUNALIELLA SALINA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dunaliella capsules (in mice)
Trial: 16413556
Drug: Beta-carotene-deficient Dunaliella
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene-deficient Dunaliella capsules (second trial)
Trial: 12883126
Drug: Sildenafil treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil treatment taken as required before sexual activity, up to two times per week
Trial: 12883126
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in sexual self-confidence and partner's wish to continue treatment
Trial: 11052587
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg transdermal nicotine patches
Trial: 1418071
Drug: Pirenzepine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (75 mg/d)
Trial: 1418072
Drug: Pirenzepine (greater
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (greater than 75 mg/d)
Trial: 29504820
Drug: Three-step reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-step reduction (TSR) therapy of integrated Chinese and Western Medicine
Trial: 30738826
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of antihypertensive medication
Trial: 26758532
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of antihypertensive medication
Trial: 26758532
Drug: Complete discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete discontinuation of all antihypertensive medication
Trial: 21897344
Drug: Oxiplex gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiplex gel (treatment group)
Trial: 19639351
Drug: Non-switchers (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-switchers (continued treatment with atorvastatin)
Trial: 17604363
Drug: PEG‐IFN‐alpha‐2b (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐alpha‐2b (100 microg weekly) alone or in combination with lamivudine (100 mg daily)
Trial: 15166128
Drug: Recombinant FSH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant FSH (rFSH) treatment
Trial: 11488938
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (3000 microg retinol equivalent), iron (30 mg), and folate (400 microg)
Trial: 11488938
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (iron (30 mg) and folate (400 microg))
Trial: 8161479
Drug: Zofenopril calcium
RxNorm normalized name: zofenopril calcium
DrugBank: Zofenopril (DB13166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril calcium (7.5-30 mg twice a day)
Trial: 2661184
Drug: Ipriflavone (Osteofix)
RxNorm normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipriflavone (Osteofix) 600 mg/day for 6 months
Trial: 30733029
Drug: ACL reconstruction
RxNorm normalized name: CONSTRICTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACL reconstruction and nonsurgical medial compartment treatment (Group 2, n = 54)
Trial: 26977029
Drug: TIVA (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIVA (total intravenous anaesthesia) with propofol and remifentanil
Trial: 26977029
Drug: CIIA (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIIA (combined intravenous and inhaled anaesthesia) with sevoflurane and remifentanil
Trial: 22328192
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg modified-release metoclopramide tablet every 24 h
Trial: 22328192
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg immediate-release metoclopramide tablet every 8 h
Trial: 22328192
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg modified-release metoclopramide tablet
Trial: 22328192
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg immediate-release metoclopramide tablet
Trial: 19760415
Drug: I-131 under
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-131 under rhTSH stimulus after 4-day L-T4 withdrawal
Trial: 19760415
Drug: I-131 under
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-131 under rhTSH stimulus after furosemide (25 mg/day for 3 days) and 4-day L-T4 withdrawal
Trial: 19760415
Drug: I-131 under
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-131 under rhTSH stimulus after furosemide (25 mg/day for 3 days) and lithium (450 mg/day for 3 days) following 4-day L-T4 withdrawal
Trial: 19760415
Drug: I-131 30
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-131 30 mCi under rhTSH stimulus without L-T4 withdrawal (control group)
Trial: 17430318
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dopexamine and enteral nutrition
Trial: 11994327
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (LD) GH replacement therapy (3 microg/kg/day for 3 months, then 6 microg/kg/day for 3 months)
Trial: 11994327
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (LD) GH replacement therapy
Trial: 11994327
Drug: Conventional Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Dose (CD) GH replacement therapy (6 microg/kg/day for 3 months, then 12 microg/kg/day for 3 months)
Trial: 11994327
Drug: Conventional Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Dose (CD) GH replacement therapy
Trial: 11692352
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% with noradrenaline 1:50,000 and vasopressin 0.25 IU/mL, and midazolam sedation